A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
Assetmark Inc. raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 32.9% in the 4th quarter, ...
Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Meiragtx Holdings (MGTX – Research Report) on March 14 and set a price ...
Check Out Our Latest Analysis on Ascendis Pharma A/S Ascendis Pharma A/S Price Performance NASDAQ:ASND opened at $138.18 on Tuesday. The stock has a market cap of $8.39 billion, a P/E ratio of -19 ...
MoonLake, a clinical-stage biopharma company developing immunology therapeutics, was created by an April 2022 merger with ...
In a report released today, Derek Archila from Wells Fargo maintained a Hold rating on Zymeworks (ZYME – Research Report), with a price target ...
MT Newswires on MSN3d
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday TradingEuropean equities traded in the US as American depositary receipts were treading water late Thursday morning, edging 0.1% higher to 1,396.7 on the S&P Europe Select ADR Index. From continental Europe, ...
After hours: 7:21:52 p.m. EST Loading Chart for ASND ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback